{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:20:11Z","timestamp":1758122411922},"reference-count":37,"publisher":"Japanese Society of Toxicology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2019]]},"DOI":"10.2131\/jts.44.441","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T22:03:32Z","timestamp":1562018612000},"page":"441-457","source":"Crossref","is-referenced-by-count":1,"title":["Telemetered common marmosets is useful for the assessment of electrocardiogram parameters changes induced by multiple cardiac ion channel inhibitors"],"prefix":"10.2131","volume":"44","author":[{"given":"Kenta","family":"Watanabe","sequence":"first","affiliation":[{"name":"Preclinical Research Unit, Sumitomo Dainippon Pharma Co., Ltd."},{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Tsubouchi","sequence":"additional","affiliation":[{"name":"Preclinical Research Unit, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Yamada","sequence":"additional","affiliation":[{"name":"Preclinical Research Unit, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Hinoi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuru","family":"Miyawaki","sequence":"additional","affiliation":[{"name":"Preclinical Research Unit, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S. and Teramura, T. (2010): A comparison of pharmacokinetics between humans and monkeys. Drug Metab. Dispos., <b>38<\/b>, 308-316.","DOI":"10.1124\/dmd.109.028829"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Ando, K., Hombo, T., Kanno, A., Ikeda, H., Imaizumi, M., Shimizu, N., Sakamoto, K., Kitani, S., Yamamoto, Y., Hizume, S., Nakai, K., Kitayama, T. and Yamamoto, K. (2005a): QT PRODACT: <i>in vivo<\/i> QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J. Pharmacol. Sci., <b>99<\/b>, 487-500.","DOI":"10.1254\/jphs.QT-A4"},{"key":"3","unstructured":"Ando, K., Unakami, S., Obo, M., Sasaki, A., Makita, Y., Yamamoto, Y. and Hayashi, K. (2005b): QT-prolongation effect of orally administered terfenadine in conscious cynomolgus monkeys \u2013interaction with ketoconazole-. Adv. Anim. Cardiol., <b>38<\/b>, 9-20."},{"key":"4","doi-asserted-by":"crossref","unstructured":"Ando, K., Nakamura, Y., Hagiwara-Nagasawa, M., Harada, H., Miyamoto, H., Inamura, N., Takagi, K., Goto, A., Chiba, K., Lubna, N.J., Izumi-Nakaseko, H., Naito, A.T. and Sugiyama, A. (2018): Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine. J. Toxicol. Sci., <b>43<\/b>, 183-192.","DOI":"10.2131\/jts.43.183"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bergenholm, L., Parkinson, J., Mettetal, J., Evans, N.D., Chappell, M.J. and Collins, T. (2017): Predicting QRS and PR interval prolongations in humans using nonclinical data. Br. J. Pharmacol., <b>174<\/b>, 3268-3283.","DOI":"10.1111\/bph.13940"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Cros, C., Skinner, M., Moors, J., Lainee, P. and Valentin, J.P. (2012): Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment. Toxicol. Appl. Pharmacol., <b>265<\/b>, 200-208.","DOI":"10.1016\/j.taap.2012.10.007"},{"key":"7","doi-asserted-by":"crossref","unstructured":"El Amrani, A.I., El Amrani-Callens, F., Loriot, S., Singh, P. and Forster, R. (2016): QT interval correction for drug-induced changes in body temperature during integrated cardiovascular safety assessment in regulatory toxicology studies in dogs: A case study. J. Pharmacol. Toxicol. Methods, <b>81<\/b>, 136-143.","DOI":"10.1016\/j.vascn.2016.04.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Fosgerau, K., Weber, U.J., Gotfredsen, J.W., Jayatissa, M., Buus, C., Kristensen, N.B., Vestergaard, M., Teschendorf, P., Schneider, A., Hansen, P., Rauns\u00f8, J., K\u00f8ber, L., Torp-Pedersen, C. and Videbaek, C. (2010): Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist. BMC Cardiovasc. Disord., <b>10<\/b>, 51.","DOI":"10.1186\/1471-2261-10-51"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gotta, V., Yu, Z., Cools, F., van Ammel, K., Gallacher, D.J., Visser, S.A., Sannajust, F., Morissette, P., Danhof, M. and van der Graaf, P.H. (2016): Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation. Pharmacol. Res. Perspect., <b>4<\/b>, e00270.","DOI":"10.1002\/prp2.270"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Heath, B.M., Cui, Y., Worton, S., Lawton, B., Ward, G., Ballini, E., Doe, C.P., Ellis, C., Patel, B.A. and McMahon, N.C. (2011): Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical. J. Pharmacol. Toxicol. Methods, <b>63<\/b>, 258-268.","DOI":"10.1016\/j.vascn.2010.12.004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Hegarty, J., Walsh, E., Burton, A., Murphy, S., O\u2019gorman, F. and McPolin, G. (2009): Nurses\u2019 knowledge of inadvertent hypothermia. AORN J., <b>89<\/b>, 701-704, 707-713.","DOI":"10.1016\/j.aorn.2008.09.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Himmel, H.M., Bussek, A., Hoffmann, M., Beckmann, R., Lohmann, H., Schmidt, M. and Wettwer, E. (2012): Field and action potential recordings in heart slices: correlation with established <i>in vitro<\/i> and <i>in vivo<\/i> models. Br. J. Pharmacol., <b>166<\/b>, 276-296.","DOI":"10.1111\/j.1476-5381.2011.01775.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Holzgrefe, H.H., Cavero, I., Gleason, C.R., Warner, W.A., Buchanan, L.V., Gill, M.W., Burkett, D.E. and Durham, S.K. (2007): Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. J. Pharmacol. Toxicol. Methods, <b>55<\/b>, 159-175.","DOI":"10.1016\/j.vascn.2006.05.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Honda, M., Komatsu, R., Holzgrefe, H.H., Yamada, Y., Isobe, T., Kimura, K., Itoh, T., Tamaoki, N. and Tabo, M. (2010): Application of probabilistic analysis for precisely correcting the QT interval for heart rate in telemetered common marmosets. J. Pharmacol. Toxicol. Methods, <b>61<\/b>, 264-270.","DOI":"10.1016\/j.vascn.2010.01.005"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Hoppu, K., Tikanoja, T., Tapanainen, P., Remes, M., Saarenp\u00e4\u00e4-Heikkil\u00e4, O. and Kouvalainen, K. (1991): Accidental astemizole overdose in young children. Lancet, <b>338<\/b>, 538-540.","DOI":"10.1016\/0140-6736(91)91101-Y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Horii, I., Kito, G., Hamada, T., Jikuzono, T., Kobayashi, K. and Hashimoto, K. (2002): Development of telemetry system in the common marmoset--cardiovascular effects of astemizole and nicardipine. J. Toxicol. Sci., <b>27<\/b>, 123-130.","DOI":"10.2131\/jts.27.123"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Isobe, T., Honda, M., Komatsu, R. and Tabo, M. (2018): Conduction and contraction properties of human iPS cell-derived cardiomyocytes: analysis by motion field imaging compared with the guinea-pig isolated heart model. J. Toxicol. Sci., <b>43<\/b>, 493-506.","DOI":"10.2131\/jts.43.493"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Johnston, J., Pal, S. and Nagele, P. (2013): Perioperative torsade de pointes: a systematic review of published case reports. Anesth. Analg., <b>117<\/b>, 559-564.","DOI":"10.1213\/ANE.0b013e318290c380"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Komatsu, R., Honda, M., Holzgrefe, H.H., Kubo, J., Yamada, Y., Isobe, T., Kimura, K., Itoh, T., Tamaoki, N. and Tabo, M. (2010): Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. J. Pharmacol. Toxicol. Methods, <b>61<\/b>, 271-276.","DOI":"10.1016\/j.vascn.2010.01.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S. and Brown, A.M. (2013): MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep., <b>3<\/b>, 2100.","DOI":"10.1038\/srep02100"},{"key":"21","unstructured":"Li, M. and Ramos, L.G. (2017): Drug-induced QT prolongation and torsades de pointes. P&amp;T, <b>42<\/b>, 473-477."},{"key":"22","doi-asserted-by":"crossref","unstructured":"Li, Z., Ridder, B.J., Han, X., Wu, W.W., Sheng, J., Tran, P.N., Wu, M., Randolph, A., Johnstone, R.H., Mirams, G.R., Kuryshev, Y., Kramer, J., Wu, C., Crumb, W.J. Jr. and Strauss, D.G. (2019): Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative. Clin. Pharmacol. Ther., <b>105<\/b>, 466-475.","DOI":"10.1002\/cpt.1184"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Lions, S., Dragu, R., Carsenty, Y., Zukermann, R. and Aronson, D. (2018): Determinants of cardiac repolarization and risk for ventricular arrhythmias during mild therapeutic hypothermia. J. Crit. Care, <b>46<\/b>, 151-156.","DOI":"10.1016\/j.jcrc.2018.03.014"},{"key":"24","doi-asserted-by":"crossref","unstructured":"McComb, J.M., McGovern, B., McGowan, J.B., Ruskin, J.N. and Garan, H. (1987): Electrophysiologic effects of d-sotalol in humans. J. Am. Coll. Cardiol., <b>10<\/b>, 211-217.","DOI":"10.1016\/S0735-1097(87)80182-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"O\u2019Hara, T., Vir\u00e1g, L., Varr\u00f3, A. and Rudy, Y. (2011): Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLOS Comput. Biol., <b>7<\/b>, e1002061.","DOI":"10.1371\/journal.pcbi.1002061"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Priest, B.T. and McDermott, J.S. (2015): Cardiac ion channels. Channels (Austin), <b>9<\/b>, 352-359.","DOI":"10.1080\/19336950.2015.1076597"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., Siegl, P.K., Strang, I., Sullivan, A.T., Wallis, R., Camm, A.J. and Hammond, T.G. (2003): Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., <b>58<\/b>, 32-45.","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Sahar, D.I., Reiffel, J.A., Bigger, J.T. Jr., Squatrito, A. and Kidwell, G.A. (1989): Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. Am. Heart J., <b>117<\/b>, 562-568.","DOI":"10.1016\/0002-8703(89)90729-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Saito, A. (2015): The marmoset as a model for the study of primate parental behavior. Neurosci. Res., <b>93<\/b>, 99-109.","DOI":"10.1016\/j.neures.2014.12.011"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Salerno, D.M., Granrud, G., Sharkey, P., Krejci, J., Larson, T., Erlien, D., Berry, D. and Hodges, M. (1986): Pharmacodynamics and side effects of flecainide acetate. Clin. Pharmacol. Ther., <b>40<\/b>, 101-107.","DOI":"10.1038\/clpt.1986.145"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Saviuc, P., Danel, V. and Dixmerias, F. (1993): Prolonged QT interval and torsade de pointes following astemizole overdose. J. Toxicol. Clin. Toxicol., <b>31<\/b>, 121-125.","DOI":"10.3109\/15563659309000380"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Tabo, M., Hara, T., Sone, S., Shishido, N., Kuramoto, S., Nakano, K., Onodera, H., Kimura, K. and Kobayashi, K. (2008): Prediction of drug-induced QT interval prolongation in telemetered common marmosets. J. Toxicol. Sci., <b>33<\/b>, 315-325.","DOI":"10.2131\/jts.33.315"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Toyoshima, S., Kanno, A., Kitayama, T., Sekiya, K., Nakai, K., Haruna, M., Mino, T., Miyazaki, H., Yano, K. and Yamamoto, K. (2005): QT PRODACT: <i>in vivo<\/i> QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sci., <b>99<\/b>, 459-471.","DOI":"10.1254\/jphs.QT-A2"},{"key":"34","doi-asserted-by":"crossref","unstructured":"van der Linde, H.J., Van Deuren, B., Teisman, A., Towart, R. and Gallacher, D.J. (2008): The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br. J. Pharmacol., <b>154<\/b>, 1474-1481.","DOI":"10.1038\/bjp.2008.265"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Van Deuren, B., Van Ammel, K., Somers, Y., Cools, F., Straetemans, R., van der Linde, H.J. and Gallacher, D.J. (2009): The fentanyl\/etomidate-anaesthetised beagle (FEAB) dog: a versatile <i>in vivo<\/i> model in cardiovascular safety research. J. Pharmacol. Toxicol. Methods, <b>60<\/b>, 11-23.","DOI":"10.1016\/j.vascn.2009.04.195"},{"key":"36","doi-asserted-by":"publisher","unstructured":"Webster, R., Allan, G., Anto-Awuakye, K., Harrison, A., Kidd, T., Leishman, D., Phipps, J. and Walker, D. (2001): Pharmacokinetic\/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica, <b>31<\/b>, 633-650.","DOI":"10.1080\/00498250110054632"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Vorperian, V.R., Gong, Q., Zhang, S. and January, C.T. (1999): Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J. Cardiovasc. Electrophysiol., <b>10<\/b>, 836-843.","DOI":"10.1111\/j.1540-8167.1999.tb00264.x"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/44\/7\/44_441\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T03:24:27Z","timestamp":1562383467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/44\/7\/44_441\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.44.441","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}